Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Genome Medicine|May 29, 2026
Preservation and clonal behavior of extrachromosomal DNA in patient-derived xenograft models of childhood cancersRishaan Kenkre, Owen S Chapman, Eugene Yui-Ching Chow, et al.
Seminars in Arthritis and Rheumatism|December 22, 2023
Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseasesSuellen A Lyne, Kevin Yip, Vasilis S Vasiliou, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
A Manifold-Based Measure of Transcriptional Entropy for Quantifying Aging in Single CellsYilin Yang, Paul R Hess, Sijia Huang, et al.
Rheumatology (Oxford, England)|February 25, 2023
Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment-specific patient-reported outcome measureSusan Bridgewater, Michael A Shepherd, Jill Dawson, et al.
Biorxiv : the Preprint Server for Biology|January 9, 2026
Aging-induced hepatocyte CD44 drives IL6/STAT3 signaling and associates with impaired neighboring T cell functionArmin Gandhi, Kathryn Lande, Yichen Li, et al.
Medrxiv : the Preprint Server for Health Sciences|August 8, 2025
Extrachromosomal DNA associates with poor survival across a broad spectrum of childhood solid tumorsOwen S Chapman, Sunita Sridhar, Eugene Yui-Ching Chow, et al.
Cell Reports|April 28, 2023
PSGL-1 attenuates early TCR signaling to suppress CD8<sup>+</sup> T cell progenitor differentiation and elicit terminal CD8<sup>+</sup> T cell exhaustionJennifer L Hope, Dennis C Otero, Eun-Ah Bae, et al.
Seminars in Arthritis and Rheumatism|July 13, 2021
Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain setJoanna Tieu, Jonathan Tl Cheah, Rachel J Black, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 25, 2023
2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is IneffectiveCharles P Hannon, Susan M Goodman, Matthew S Austin, et al.
The Journal of Arthroplasty|October 1, 2023
2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is IneffectiveCharles P Hannon, Susan M Goodman, Matthew S Austin, et al.
Pageof 4